Clinical Trial Update: A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting results from a 24-week arterial stiffness study of the inhaled corticosteroid/long-acting beta-agonist combination fluticasone fu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Fluticasone Furoate/Vilanterol (fluticasone furoate/vilanterol)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2015-07-10